Q2 2026 saw lower Adjusted EBITDA and net revenue due to unfavorable payer mix, higher uninsured volumes, and softness in elective procedures, despite operational improvements and new Medicaid payment programs. Guidance for 2026 was revised downward, reflecting ongoing macroeconomic and payer mix headwinds.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.